Dosage by Weight Guide

Does Body Weight Affect Psilocybin Dosage?

The short answer is: much less than most people expect. Psilocybin's pharmacological mechanism makes it fundamentally different from substances where body weight is a reliable dose predictor.

When you consume psilocybin mushrooms, the compound is converted in the gut and liver into psilocin, its active metabolite. Psilocin then crosses the blood-brain barrier and binds primarily to 5-HT2A serotonin receptors in the cortex. The subjective intensity of an experience depends on how strongly those receptors are activated — and receptor density in the brain does not scale proportionally with body mass. A person who weighs 130 kg does not have twice the brain receptor density of someone who weighs 65 kg, and they are not going to need twice the dose.

This is in direct contrast to alcohol, which distributes through total body water. Because a larger person contains more body water, alcohol is diluted more effectively — making weight a meaningful predictor of blood alcohol concentration. Psilocybin does not distribute this way. It is not a useful comparison.

This is also reflected in clinical research. Major psilocybin trials at Johns Hopkins University and Imperial College London use flat-dose protocols: typically 25 mg of synthetic psilocybin per session, applied uniformly to participants regardless of body weight. If weight were a strong predictor of response, research teams running rigorous studies would adjust for it. The consistent use of fixed doses across varying body weights reflects the consensus that the relationship is weak.

What actually drives response variability between individuals is covered in a later section. Body weight is a minor, peripheral factor — not the primary lens through which to calibrate a dose.

Standard Dosage Tiers by Dried Weight

The following tiers represent the harm-reduction community consensus for dried Psilocybe cubensis, the most commonly encountered species. Potency varies between species and even between individual flushes of the same species, so these figures should be treated as approximate guidelines rather than precise measurements. All weights refer to dried mushroom material.

These tiers apply to dried Psilocybe cubensis specifically. More potent species such as Psilocybe azurescens or Psilocybe semilanceata contain significantly higher psilocybin concentrations by weight and require substantially lower doses to achieve equivalent effects.

When Weight May Matter

While the weight-dose relationship is weak overall, there are edge cases where body size may warrant modest consideration.

For individuals at the extremes of body weight — roughly below 50 kg (110 lbs) or above 120 kg (265 lbs) — a conservative adjustment of approximately 10–15% from a standard mid-tier dose may be reasonable. A very small person might choose to start toward the lower end of a dosage tier; a very large person might note that the standard low-end figure is a comfortable anchor point rather than a ceiling.

However, this is not proportional scaling. The adjustment is small, conservative, and applies only at genuine extremes of body size. It is not a formula. Attempting to calculate a precise mg/kg weight-adjusted dose for psilocybin mushrooms is a false precision — the natural variation in psilocybin content between individual mushrooms, even within the same batch, is itself large enough to render such calculations meaningless.

The more important principle: regardless of body weight, first-time users should always begin at the low tier (0.5–1.0 g) and assess their individual response before considering higher doses on future occasions.

Factors That Actually Predict Response Better Than Weight

If you want to anticipate how a given dose is likely to feel, the following factors are far more informative than body mass:

• Individual 5-HT2A receptor sensitivity. The density and sensitivity of serotonin receptors varies between people at a neurobiological level. This is not something that can be measured at home — it means that two people of identical weight and health status can have dramatically different experiences from the same dose.
• Prior psychedelic experience. Tolerance to psilocybin develops rapidly with repeated use. Someone who used mushrooms a week ago will likely have a significantly attenuated experience from the same dose. Conversely, a first-time user with no prior exposure may be more sensitive.
• Set and setting. Mindset (emotional state, intentions, anxiety levels) and the physical and social environment exert a powerful influence on the quality and intensity of an experience. A supportive, calm environment with a trusted companion produces meaningfully different outcomes than an unprepared or stressful one.
• Medication interactions. SSRIs and SNRIs (common antidepressants) interact with psilocybin in complex ways — some users report significantly blunted effects, while abrupt discontinuation before use carries its own risks. MAOIs can potentiate psilocybin substantially and represent a serious safety concern. Anyone taking psychiatric medications should research interactions carefully before considering psilocybin use.
• Stomach contents. Consuming mushrooms on an empty stomach generally produces faster onset (30–45 minutes) and sometimes a more intense initial peak. A full stomach can delay onset by an hour or more and may reduce peak intensity. This is a more immediate and predictable variable than body weight.
• CYP2D6 enzyme activity. Psilocin is partly metabolized by the CYP2D6 enzyme, which shows significant genetic variation across populations. Individuals who are poor metabolizers may experience longer or more pronounced effects; ultra-rapid metabolizers may find effects shorter-lived. This genetic variability is not reflected in body weight.

Harm Reduction Principles for Dosing

Regardless of body weight, the following principles reduce risk and support safer experiences:

• Start low, go slow. For any new batch of mushrooms, any new setting, or any new period of use after a break, begin at the lower end of your intended tier. Potency varies between batches and you cannot compensate for underestimating a dose once you have taken it.
• Do not redose too quickly. Onset can be delayed — particularly on a full stomach — by 60 to 90 minutes or more. Taking a second dose because "nothing is happening yet" is one of the most common causes of unexpectedly difficult experiences. Wait at least 90 minutes before considering any supplemental dose.
• You can always take more next time, never less this time. This principle applies at every experience level. If you are uncertain whether a dose will be sufficient, err on the side of caution and plan a follow-up session at a higher dose if needed. Adjusting upward on a future occasion is always possible; reversing an unexpectedly strong experience is not.
• Have a trusted person present. Particularly at moderate to high doses, having a sober, experienced companion who knows what you have taken and can remain calm if difficulties arise substantially reduces risk. Tripping alone — especially at higher doses or in unfamiliar environments — removes an important safety layer.
• Know your contraindications. A personal or family history of psychosis or bipolar disorder, current use of lithium or MAOIs, and heart conditions are among the factors that warrant particular caution. These represent risk factors that are independent of body weight and more clinically significant.

Accurate dosing begins with a reliable scale — a kitchen scale with 0.1 g precision at minimum, ideally 0.01 g precision for microdose work. Estimating mushroom weight by eye is not reliable. Investing in a precision scale is one of the most practical harm-reduction steps available.